NHS National Generics Pharmaceuticals - Dasatinib and Paliperidone Injection

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
21 month
Value
£27M
Sector
HEALTH
Published
27 Apr 2023
Delivery
01 May 2023 to 31 Jan 2025
Deadline
21 Feb 2023 13:00

Related Terms

Location

Geochart for 1 buyers and 5 suppliers

1 buyer

5 suppliers

Description

Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection Offer reference number: CM/PHG/22/5694 FIND A TENDER (FTS) - 2023/S 000-001392 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/22/5694/00 - Dasatinib CESW 01/05/2023 - 30/04/2024 - (12 Months) LSNE 01/05/2023 - 30/04/2024 - (12 Months) NWLN 01/05/2023 - 30/04/2024 - (12 Months) CM/PHG/22/5694/01 - Paliperidone Injection: LSNE 01/05/2023 - 31/05/2024 (13 Months) NWLN 01/05/2023 - 31/01/2025 (21 months)

Award Detail

1 Janssen Cilag (High Wycombe)
  • Value: £27,009,807
2 Zentiva Pharma (Felstead)
  • Value: £27,009,807
3 Teva (Castleford)
  • Value: £27,009,807
4 Mylan (Hatfield)
  • Value: £27,009,807
5 Mercury Pharmaceuticals (London)
  • Value: £27,009,807

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

CM_PHG_22_5694_00 Transparency Award Schedules CM_PHG_22_5694_00 Transparency Award Schedules.pdf CM_PHG_22_5694_01 Transparency Award Schedule CM_PHG_22_5694_01 Transparency Award Schedule.pdf

Reference

  • CF-1399600D0O000000rwimUAA
  • CF 101ad108-6a5b-410d-b375-4ca49a187c9e

Domains